{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363951795166011008.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1056/nejmoa1411321"}},{"identifier":{"@type":"URI","@value":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1411321"}}],"dc:title":[{"@value":"Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383951795166011008","@type":"Researcher","foaf:name":[{"@value":"A. Keith Stewart"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011137","@type":"Researcher","foaf:name":[{"@value":"S. Vincent Rajkumar"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011028","@type":"Researcher","foaf:name":[{"@value":"Meletios A. Dimopoulos"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011011","@type":"Researcher","foaf:name":[{"@value":"Tamás Masszi"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011136","@type":"Researcher","foaf:name":[{"@value":"Ivan Špička"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011139","@type":"Researcher","foaf:name":[{"@value":"Albert Oriol"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011027","@type":"Researcher","foaf:name":[{"@value":"Roman Hájek"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011010","@type":"Researcher","foaf:name":[{"@value":"Laura Rosiñol"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011013","@type":"Researcher","foaf:name":[{"@value":"David S. Siegel"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011025","@type":"Researcher","foaf:name":[{"@value":"Georgi G. Mihaylov"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011022","@type":"Researcher","foaf:name":[{"@value":"Vesselina Goranova-Marinova"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011023","@type":"Researcher","foaf:name":[{"@value":"Péter Rajnics"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011014","@type":"Researcher","foaf:name":[{"@value":"Aleksandr Suvorov"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011009","@type":"Researcher","foaf:name":[{"@value":"Ruben Niesvizky"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011138","@type":"Researcher","foaf:name":[{"@value":"Andrzej J. Jakubowiak"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011029","@type":"Researcher","foaf:name":[{"@value":"Jesus F. San-Miguel"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011018","@type":"Researcher","foaf:name":[{"@value":"Heinz Ludwig"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011021","@type":"Researcher","foaf:name":[{"@value":"Michael Wang"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011020","@type":"Researcher","foaf:name":[{"@value":"Vladimír Maisnar"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011012","@type":"Researcher","foaf:name":[{"@value":"Jiri Minarik"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011015","@type":"Researcher","foaf:name":[{"@value":"William I. Bensinger"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011024","@type":"Researcher","foaf:name":[{"@value":"Maria-Victoria Mateos"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011030","@type":"Researcher","foaf:name":[{"@value":"Dina Ben-Yehuda"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011026","@type":"Researcher","foaf:name":[{"@value":"Vishal Kukreti"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011140","@type":"Researcher","foaf:name":[{"@value":"Naseem Zojwalla"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011019","@type":"Researcher","foaf:name":[{"@value":"Margaret E. Tonda"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011017","@type":"Researcher","foaf:name":[{"@value":"Xinqun Yang"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011016","@type":"Researcher","foaf:name":[{"@value":"Biao Xing"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011032","@type":"Researcher","foaf:name":[{"@value":"Philippe Moreau"}]},{"@id":"https://cir.nii.ac.jp/crid/1383951795166011031","@type":"Researcher","foaf:name":[{"@value":"Antonio Palumbo"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00284793"},{"@type":"EISSN","@value":"15334406"}],"prism:publicationName":[{"@value":"New England Journal of Medicine"}],"dc:publisher":[{"@value":"Massachusetts Medical Society"}],"prism:publicationDate":"2015-01-08","prism:volume":"372","prism:number":"2","prism:startingPage":"142","prism:endingPage":"152"},"reviewed":"false","url":[{"@id":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1411321"}],"createdAt":"2014-12-06","modifiedAt":"2020-08-27","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050020530227665408","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360017279853559680","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360025429421847040","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Establishment and characterization of a novel patient-derived cell line from conventional central grade 3 chondrosarcoma, NCC-CS1-C1"}]},{"@id":"https://cir.nii.ac.jp/crid/1360290617632478976","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Assessment of Hazard Ratios in Oncology Clinical Trials Terminated Early for Superiority"}]},{"@id":"https://cir.nii.ac.jp/crid/1360290617671677312","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Lenalidomide and pomalidomide potently interfere with induction of myeloid‐derived suppressor cells in multiple myeloma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360290617840814208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Role of the Ubiquitin Proteasome System in the Regulation of Blood Pressure: A Review"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181474130688","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567183414927360","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567184842468224","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Phase II Clinical Trial of Lenalidomide and Dexamethasone Therapy in Japanese Elderly Patients With Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567188226175872","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits"}]},{"@id":"https://cir.nii.ac.jp/crid/1360568470444220032","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Novel p97/<scp>VCP</scp> inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib‐sensitive and ‐resistant multiple myeloma cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576118804081152","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580232401100928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Relapsed and refractory multiple myeloma: A systematic review and network meta‐analysis of the efficacy of novel therapies"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660413138432","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360849945420912768","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360853567699955712","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861704796539520","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865814747144064","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Daratumumab Treatment for “Truly Frail” Elderly Myeloma Patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1361694371239518464","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets"}]},{"@id":"https://cir.nii.ac.jp/crid/1390002184888812416","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma"}]},{"@id":"https://cir.nii.ac.jp/crid/1390003825207849088","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Diagnosis and Treatment of Multiple Myeloma for Spinal Surgeons"},{"@language":"ja","@value":"脊髄外科医のための多発性骨髄腫の診断と治療"}]},{"@id":"https://cir.nii.ac.jp/crid/1390026271633105664","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Cancer Treatment-Related Ischemic Heart Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681426661504","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"VIII．多発性骨髄腫に対する新規治療薬"},{"@language":"en","@value":"VIII. Novel Drugs for Multiple Myeloma"},{"@value":"多発性骨髄腫に対する新規治療薬"},{"@language":"ja-Kana","@value":"タハツセイ コツズイシュ ニ タイスル シンキ チリョウヤク"}]},{"@id":"https://cir.nii.ac.jp/crid/1390288215573541120","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Vancomycin Intoxication and Cefepime-induced Encephalopathy Treated by Abdominal Drainage of Massive Ascites in Addition to Online Hemodiafiltration"}]},{"@id":"https://cir.nii.ac.jp/crid/1390566775161036544","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Cancer Therapeutics-Related Cardiac Dysfunction　― Insights From Bench and Bedside of Onco-Cardiology ―"}]},{"@id":"https://cir.nii.ac.jp/crid/1390568456357543424","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Multiple Myeloma with Central Nervous System Relapse Early after Autologous Stem Cell Transplantation: A Case Report and Literature Review"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1056/nejmoa1411321"},{"@type":"CROSSREF","@value":"10.2531/spinalsurg.34.134_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.1182/blood.2021015220_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.1007/s13577-024-01152-0_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.1001/jamanetworkopen.2020.8633_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.1111/bjh.16881_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.3390/ijms21155358_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.6233-20_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.2169/naika.105.1255_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.7793/jcad.32.003_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.1007/s12185-016-2149-1_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.1038/s41408-018-0127-y_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.1253/circj.cj-20-0467_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.1097/ftd.0000000000000499_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.1111/cas.14154_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.3390/cancers13112712_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.5646-20_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.1111/bjh.18654_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.1111/bjh.13900_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.1111/cas.14139_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.18632/oncotarget.24160_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.1111/bjh.16878_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.1080/10428194.2022.2038373_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.1177/20406207221104584_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.3390/life14030389_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"},{"@type":"CROSSREF","@value":"10.1155/2019/6084012_references_DOI_TX5zBqoMn5F8OjxrqLdwBmiw7NM"},{"@type":"CROSSREF","@value":"10.3960/jslrt.19031_references_DOI_PqDQxsdANP558aITTeNVHtrcxRA"}]}